APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Therapy-based Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oligonucleotide Therapy-based Drug Industry Research Report 2026

20 December 2025143 pages

Choose your research edition.

Industry ResearchOligonucleotide Therapy-based Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Therapy-based Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Therapy-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Therapy-based Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Therapy-based Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Oligonucleotide Therapy-based Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Oligonucleotide Therapy-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oligonucleotide Therapy-based Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oligonucleotide Therapy-based Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oligonucleotide Therapy-based Drug include Sobi, Novartis, Pfizer, Biogen, Sylentis, Silence Therapeutics, Secarna, Sarepta Therapeutics and Regulus Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Oligonucleotide Therapy-based Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oligonucleotide Therapy-based Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oligonucleotide Therapy-based Drug Market by Company

Sobi

Novartis

Pfizer

Biogen

Sylentis

Silence Therapeutics

Secarna

Sarepta Therapeutics

Regulus Therapeutics

ProQR

Nippon Shinyaku

Moderna Therapeutics

MiNA Therapeutics

Jazz Pharmaceuticals

Ionis Pharmaceuticals

Dicerna

CureVac

BioNTech

Arrowhead

Alnylam

Oligonucleotide Therapy-based Drug Segment by Type

mRNA

siRNA

Antisense Oligonucleotides (ASO)

Oligonucleotide Therapy-based Drug Segment by Application

hATTR

Neuromuscular Diseases

COVID-19

Other

Oligonucleotide Therapy-based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapy-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapy-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapy-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Oligonucleotide Therapy-based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2021-2026) Table 7. Global Oligonucleotide Therapy-based Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2027-2032) Table 9. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021-2026) Table 11. Global Oligonucleotide Therapy-based Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2027-2032) Table 13. Global Oligonucleotide Therapy-based Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Oligonucleotide Therapy-based Drug Market Share by Region (2021-2026) Table 16. Global Oligonucleotide Therapy-based Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Oligonucleotide Therapy-based Drug Market Share by Region (2027-2032) Table 18. Oligonucleotide Therapy-based Drug Industry Trends Table 19. Oligonucleotide Therapy-based Drug Industry Drivers Table 20. Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges Table 21. Oligonucleotide Therapy-based Drug Market Restraints Table 22. Global Top Oligonucleotide Therapy-based Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Players (2021-2026) Table 24. Global Oligonucleotide Therapy-based Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Oligonucleotide Therapy-based Drug, Headquarters and Area Served Table 26. Global Oligonucleotide Therapy-based Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Oligonucleotide Therapy-based Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. Sobi Company Information Table 46. Sobi Business Overview Table 47. Sobi Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 48. Sobi Oligonucleotide Therapy-based Drug Product Portfolio Table 49. Sobi Recent Developments Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 53. Novartis Oligonucleotide Therapy-based Drug Product Portfolio Table 54. Novartis Recent Developments Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 58. Pfizer Oligonucleotide Therapy-based Drug Product Portfolio Table 59. Pfizer Recent Developments Table 60. Biogen Company Information Table 61. Biogen Business Overview Table 62. Biogen Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 63. Biogen Oligonucleotide Therapy-based Drug Product Portfolio Table 64. Biogen Recent Developments Table 65. Sylentis Company Information Table 66. Sylentis Business Overview Table 67. Sylentis Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 68. Sylentis Oligonucleotide Therapy-based Drug Product Portfolio Table 69. Sylentis Recent Developments Table 70. Silence Therapeutics Company Information Table 71. Silence Therapeutics Business Overview Table 72. Silence Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 73. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 74. Silence Therapeutics Recent Developments Table 75. Secarna Company Information Table 76. Secarna Business Overview Table 77. Secarna Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 78. Secarna Oligonucleotide Therapy-based Drug Product Portfolio Table 79. Secarna Recent Developments Table 80. Sarepta Therapeutics Company Information Table 81. Sarepta Therapeutics Business Overview Table 82. Sarepta Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 83. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 84. Sarepta Therapeutics Recent Developments Table 85. Regulus Therapeutics Company Information Table 86. Regulus Therapeutics Business Overview Table 87. Regulus Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 88. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 89. Regulus Therapeutics Recent Developments Table 90. ProQR Company Information Table 91. ProQR Business Overview Table 92. ProQR Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 93. ProQR Oligonucleotide Therapy-based Drug Product Portfolio Table 94. ProQR Recent Developments Table 95. Nippon Shinyaku Company Information Table 96. Nippon Shinyaku Business Overview Table 97. Nippon Shinyaku Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 98. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio Table 99. Nippon Shinyaku Recent Developments Table 100. Moderna Therapeutics Company Information Table 101. Moderna Therapeutics Business Overview Table 102. Moderna Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 103. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 104. Moderna Therapeutics Recent Developments Table 105. MiNA Therapeutics Company Information Table 106. MiNA Therapeutics Business Overview Table 107. MiNA Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 108. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 109. MiNA Therapeutics Recent Developments Table 110. Jazz Pharmaceuticals Company Information Table 111. Jazz Pharmaceuticals Business Overview Table 112. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 113. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio Table 114. Jazz Pharmaceuticals Recent Developments Table 115. Ionis Pharmaceuticals Company Information Table 116. Ionis Pharmaceuticals Business Overview Table 117. Ionis Pharmaceuticals Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 118. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio Table 119. Ionis Pharmaceuticals Recent Developments Table 120. Dicerna Company Information Table 121. Dicerna Business Overview Table 122. Dicerna Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 123. Dicerna Oligonucleotide Therapy-based Drug Product Portfolio Table 124. Dicerna Recent Developments Table 125. CureVac Company Information Table 126. CureVac Business Overview Table 127. CureVac Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 128. CureVac Oligonucleotide Therapy-based Drug Product Portfolio Table 129. CureVac Recent Developments Table 130. BioNTech Company Information Table 131. BioNTech Business Overview Table 132. BioNTech Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 133. BioNTech Oligonucleotide Therapy-based Drug Product Portfolio Table 134. BioNTech Recent Developments Table 135. Arrowhead Company Information Table 136. Arrowhead Business Overview Table 137. Arrowhead Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 138. Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio Table 139. Arrowhead Recent Developments Table 140. Alnylam Company Information Table 141. Alnylam Business Overview Table 142. Alnylam Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026) & (US$ Million) Table 143. Alnylam Oligonucleotide Therapy-based Drug Product Portfolio Table 144. Alnylam Recent Developments Table 145. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oligonucleotide Therapy-based Drug Product Image Figure 5. Global Oligonucleotide Therapy-based Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Oligonucleotide Therapy-based Drug Market Share by Type: 2025 VS 2032 Figure 7. mRNA Product Figure 8. siRNA Product Figure 9. Antisense Oligonucleotides (ASO) Product Figure 10. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Oligonucleotide Therapy-based Drug Market Share by Application: 2025 VS 2032 Figure 12. hATTR Product Figure 13. Neuromuscular Diseases Product Figure 14. COVID-19 Product Figure 15. Other Product Figure 16. Global Oligonucleotide Therapy-based Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 17. Global Oligonucleotide Therapy-based Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Oligonucleotide Therapy-based Drug Market Share by Region: 2025 VS 2032 Figure 19. Global Oligonucleotide Therapy-based Drug Market Share by Players in 2025 Figure 20. Global Oligonucleotide Therapy-based Drug Manufacturers Established Date Figure 21. Global Top 5 and 10 Oligonucleotide Therapy-based Drug Players Market Share by Revenue in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. North America Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 25. United States Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Canada Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Mexico Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 28. Europe Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 30. Germany Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. France Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. U.K. Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Italy Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Spain Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Russia Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Netherlands Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Nordic Countries Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 40. China Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Japan Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. South Korea Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 45. Australia Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. China Taiwan Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. Southeast Asia Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 50. Brazil Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Argentina Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Chile Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Colombia Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Peru Oligonucleotide Therapy-based Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Sobi Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 56. Novartis Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 57. Pfizer Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 58. Biogen Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 59. Sylentis Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 60. Silence Therapeutics Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 61. Secarna Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 62. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 63. Regulus Therapeutics Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 64. ProQR Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 65. Nippon Shinyaku Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 66. Moderna Therapeutics Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 67. MiNA Therapeutics Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 68. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 69. Ionis Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 70. Dicerna Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 71. CureVac Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 72. BioNTech Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 73. Arrowhead Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026) Figure 74. Alnylam Revenue Growth Rate in Oligonucleotide Therapy-based Drug Business (2021-2026)

Scope & coverage.

Types
  • mRNA
  • siRNA
  • Antisense Oligonucleotides (ASO)
Applications
  • hATTR
  • Neuromuscular Diseases
  • COVID-19
  • Other
Companies covered
  • Sobi
  • Novartis
  • Pfizer
  • Biogen
  • Sylentis
  • Silence Therapeutics
  • Secarna
  • Sarepta Therapeutics
  • Regulus Therapeutics
  • ProQR
  • Nippon Shinyaku
  • Moderna Therapeutics
  • MiNA Therapeutics
  • Jazz Pharmaceuticals
  • Ionis Pharmaceuticals
  • Dicerna
  • CureVac
  • BioNTech
  • Arrowhead
  • Alnylam

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Oligonucleotide Therapy-based Drug by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 mRNA
  5. 2.2.3 siRNA
  6. 2.2.4 Antisense Oligonucleotides (ASO)
  7. 2.3 Oligonucleotide Therapy-based Drug by Application
  8. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  9. 2.3.2 hATTR
  10. 2.3.3 Neuromuscular Diseases
  11. 2.3.4 COVID-19
  12. 2.3.5 Other
  13. 2.4 Assumptions and Limitations
3 Oligonucleotide Therapy-based Drug Breakdown Data by Type
  1. 3.1 Global Oligonucleotide Therapy-based Drug Historic Market Size by Type (2021-2026)
  2. 3.2 Global Oligonucleotide Therapy-based Drug Forecasted Market Size by Type (2027-2032)
4 Oligonucleotide Therapy-based Drug Breakdown Data by Application
  1. 4.1 Global Oligonucleotide Therapy-based Drug Historic Market Size by Application (2021-2026)
  2. 4.2 Global Oligonucleotide Therapy-based Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Oligonucleotide Therapy-based Drug Market Perspective (2021-2032)
  2. 5.2 Global Oligonucleotide Therapy-based Drug Growth Trends by Region
  3. 5.2.1 Global Oligonucleotide Therapy-based Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Oligonucleotide Therapy-based Drug Historic Market Size by Region (2021-2026)
  5. 5.2.3 Oligonucleotide Therapy-based Drug Forecasted Market Size by Region (2027-2032)
  6. 5.3 Oligonucleotide Therapy-based Drug Market Dynamics
  7. 5.3.1 Oligonucleotide Therapy-based Drug Industry Trends
  8. 5.3.2 Oligonucleotide Therapy-based Drug Market Drivers
  9. 5.3.3 Oligonucleotide Therapy-based Drug Market Challenges
  10. 5.3.4 Oligonucleotide Therapy-based Drug Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Oligonucleotide Therapy-based Drug Players by Revenue
  2. 6.1.1 Global Top Oligonucleotide Therapy-based Drug Players by Revenue (2021-2026)
  3. 6.1.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Oligonucleotide Therapy-based Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Oligonucleotide Therapy-based Drug Head Office and Area Served
  6. 6.4 Global Oligonucleotide Therapy-based Drug Players, Product Type & Application
  7. 6.5 Global Oligonucleotide Therapy-based Drug Manufacturers Established Date
  8. 6.6 Global Oligonucleotide Therapy-based Drug Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Oligonucleotide Therapy-based Drug Market Size (2021-2032)
  2. 7.2 North America Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  4. 7.4 North America Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Oligonucleotide Therapy-based Drug Market Size (2021-2032)
  2. 8.2 Europe Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  4. 8.4 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size (2021-2032)
  2. 9.2 Asia-Pacific Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Oligonucleotide Therapy-based Drug Market Size (2021-2032)
  2. 10.2 South America Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  4. 10.4 South America Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size (2021-2032)
  2. 11.2 Middle East & Africa Oligonucleotide Therapy-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Sobi
  2. 12.1.1 Sobi Company Information
  3. 12.1.2 Sobi Business Overview
  4. 12.1.3 Sobi Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  5. 12.1.4 Sobi Oligonucleotide Therapy-based Drug Product Portfolio
  6. 12.1.5 Sobi Recent Developments
  7. 12.2 Novartis
  8. 12.2.1 Novartis Company Information
  9. 12.2.2 Novartis Business Overview
  10. 12.2.3 Novartis Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  11. 12.2.4 Novartis Oligonucleotide Therapy-based Drug Product Portfolio
  12. 12.2.5 Novartis Recent Developments
  13. 12.3 Pfizer
  14. 12.3.1 Pfizer Company Information
  15. 12.3.2 Pfizer Business Overview
  16. 12.3.3 Pfizer Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  17. 12.3.4 Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
  18. 12.3.5 Pfizer Recent Developments
  19. 12.4 Biogen
  20. 12.4.1 Biogen Company Information
  21. 12.4.2 Biogen Business Overview
  22. 12.4.3 Biogen Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  23. 12.4.4 Biogen Oligonucleotide Therapy-based Drug Product Portfolio
  24. 12.4.5 Biogen Recent Developments
  25. 12.5 Sylentis
  26. 12.5.1 Sylentis Company Information
  27. 12.5.2 Sylentis Business Overview
  28. 12.5.3 Sylentis Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  29. 12.5.4 Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
  30. 12.5.5 Sylentis Recent Developments
  31. 12.6 Silence Therapeutics
  32. 12.6.1 Silence Therapeutics Company Information
  33. 12.6.2 Silence Therapeutics Business Overview
  34. 12.6.3 Silence Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  35. 12.6.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  36. 12.6.5 Silence Therapeutics Recent Developments
  37. 12.7 Secarna
  38. 12.7.1 Secarna Company Information
  39. 12.7.2 Secarna Business Overview
  40. 12.7.3 Secarna Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  41. 12.7.4 Secarna Oligonucleotide Therapy-based Drug Product Portfolio
  42. 12.7.5 Secarna Recent Developments
  43. 12.8 Sarepta Therapeutics
  44. 12.8.1 Sarepta Therapeutics Company Information
  45. 12.8.2 Sarepta Therapeutics Business Overview
  46. 12.8.3 Sarepta Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  47. 12.8.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  48. 12.8.5 Sarepta Therapeutics Recent Developments
  49. 12.9 Regulus Therapeutics
  50. 12.9.1 Regulus Therapeutics Company Information
  51. 12.9.2 Regulus Therapeutics Business Overview
  52. 12.9.3 Regulus Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  53. 12.9.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  54. 12.9.5 Regulus Therapeutics Recent Developments
  55. 12.10 ProQR
  56. 12.10.1 ProQR Company Information
  57. 12.10.2 ProQR Business Overview
  58. 12.10.3 ProQR Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  59. 12.10.4 ProQR Oligonucleotide Therapy-based Drug Product Portfolio
  60. 12.10.5 ProQR Recent Developments
  61. 12.11 Nippon Shinyaku
  62. 12.11.1 Nippon Shinyaku Company Information
  63. 12.11.2 Nippon Shinyaku Business Overview
  64. 12.11.3 Nippon Shinyaku Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  65. 12.11.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
  66. 12.11.5 Nippon Shinyaku Recent Developments
  67. 12.12 Moderna Therapeutics
  68. 12.12.1 Moderna Therapeutics Company Information
  69. 12.12.2 Moderna Therapeutics Business Overview
  70. 12.12.3 Moderna Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  71. 12.12.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  72. 12.12.5 Moderna Therapeutics Recent Developments
  73. 12.13 MiNA Therapeutics
  74. 12.13.1 MiNA Therapeutics Company Information
  75. 12.13.2 MiNA Therapeutics Business Overview
  76. 12.13.3 MiNA Therapeutics Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  77. 12.13.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  78. 12.13.5 MiNA Therapeutics Recent Developments
  79. 12.14 Jazz Pharmaceuticals
  80. 12.14.1 Jazz Pharmaceuticals Company Information
  81. 12.14.2 Jazz Pharmaceuticals Business Overview
  82. 12.14.3 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  83. 12.14.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
  84. 12.14.5 Jazz Pharmaceuticals Recent Developments
  85. 12.15 Ionis Pharmaceuticals
  86. 12.15.1 Ionis Pharmaceuticals Company Information
  87. 12.15.2 Ionis Pharmaceuticals Business Overview
  88. 12.15.3 Ionis Pharmaceuticals Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  89. 12.15.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
  90. 12.15.5 Ionis Pharmaceuticals Recent Developments
  91. 12.16 Dicerna
  92. 12.16.1 Dicerna Company Information
  93. 12.16.2 Dicerna Business Overview
  94. 12.16.3 Dicerna Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  95. 12.16.4 Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
  96. 12.16.5 Dicerna Recent Developments
  97. 12.17 CureVac
  98. 12.17.1 CureVac Company Information
  99. 12.17.2 CureVac Business Overview
  100. 12.17.3 CureVac Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  101. 12.17.4 CureVac Oligonucleotide Therapy-based Drug Product Portfolio
  102. 12.17.5 CureVac Recent Developments
  103. 12.18 BioNTech
  104. 12.18.1 BioNTech Company Information
  105. 12.18.2 BioNTech Business Overview
  106. 12.18.3 BioNTech Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  107. 12.18.4 BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
  108. 12.18.5 BioNTech Recent Developments
  109. 12.19 Arrowhead
  110. 12.19.1 Arrowhead Company Information
  111. 12.19.2 Arrowhead Business Overview
  112. 12.19.3 Arrowhead Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  113. 12.19.4 Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
  114. 12.19.5 Arrowhead Recent Developments
  115. 12.20 Alnylam
  116. 12.20.1 Alnylam Company Information
  117. 12.20.2 Alnylam Business Overview
  118. 12.20.3 Alnylam Revenue in Oligonucleotide Therapy-based Drug Business (2021-2026)
  119. 12.20.4 Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
  120. 12.20.5 Alnylam Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst